Quadrant Capital »

Rapport Therapeutics shares owned by Quadrant Capital

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Quadrant Capital from 13F filings

Historical chart of Quadrant Capital investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Quadrant Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Quadrant Capital

Quarter filed Position value Share count Share price at filing
2025-09-30 $1.7k 57 29.70

More positions owned by Quadrant Capital

Ishares Tr Core S&p500 Etf (IVV)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Schwab Strategic Tr Fundamental Us L (FNDX)
J P Morgan Exchange Traded F Ultra Shrt Etf (JPST)
Alphabet Cap Stk Cl A (GOOGL)
Ishares Tr Core Msci Eafe (IEFA)
Amazon (AMZN)
Ishares Tr Core S&p Mcp Etf (IJH)
Broadcom (AVGO)
Meta Platforms Cl A (META)
Tesla Motors (TSLA)
Procter & Gamble Company (PG)
Taiwan Semiconductor Mfg Sponsored Ads (TSM)

View all positions for Quadrant Capital

Top funds holding Rapport Therapeutics

TRV GP V
FMR
Arch Venture Corp
Capital Research and Management Company - Division 3
Cormorant Asset Management
Goldman Sachs Group
Sofinnova Ventures
Johnson & Johnson
Vanguard Group
BlackRock
Baker Bros. Advisors
Siren
Trv Gp Vi
Vestal Point Capital
Polar Capital Holdings

View all funds holding Rapport Therapeutics